🌍·8h agodiscovery
Tasrif Pharmaceutical granted second US patent for CD155-targeting antibody developed with Abzena's humanisation and immunogenicity platforms
Publisher
M
Manufacturing Chemist
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Manufacturing Chemist
- Region
- Global
- Scope
- discovery
- Published
- August 4, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: Manufacturing Chemist
Scope: discovery
Related coverage
More related coverage
stocktitan.net/3h ago
Moderna vaccinates first participants in trial for Ebola strain with no vaccine
The Pharmaceutical Journal/3h ago
Best practice for prescribing drugs with dependence potential
Generics and Biosimilars Initiative/4h ago
Medicines for Europe calls for Biotech Act reforms to address ‘biosimilar void’
CIDRAP/4h ago